Nucala of GlaxoSmithKline exhibits splendid benefits to other IL-5 Inhibitors in Asthma, however flunks as a COPD Drug
A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala, which targets the IL-5 pathway, was initially approved in 2015 by the FDA to treat patients of age 12 years and older with severe asthma with an eosinophilic phenotype. Data by GSK was shown that the same medication was a better treatment in severe eosinophilic asthma in patients with similar blood eosinophil counts.
The mutation in gene is an answer to glioblastoma’s immortality
Researchers of the Universi...
